Infertility Testing and Treatment Market

Infertility Testing and Treatment Market: Introduction

• Infertility is defined as the inability to conceive naturally after one year of unprotected copulation. Within the field of reproductive state, infertility indicates a deficiency that does not compromise the physical ability of the individual, nor is it life-threatening. However, it could impact the development of individuals (both men and women), weaken their personality, and induce frustration. Around 50 million to 80 million couples suffer from infertility issues at least once in their reproductive lives. The situation of infertility is different in developing countries as compared to that in developed countries.
• Apart from the endocrinological, anatomical, immunological, and genetic issues, a substantial percentage of women suffer from preventable issues such as pelvic inflammatory diseases (PIDs), postpartum infections, sexually transmitted infections, post abortion infection, tubal damage, previous contraceptive complications, and polycystic ovary syndrome (PCOS)

Key Drivers, Restraints, and Opportunities of Global Infertility Testing and Treatment Market

• A rise in infertility and treatment awareness and the introduction of novel testing devices are key factors driving the global Infertility testing and treatment market. As per the US Census Bureau Statistics 2014, 142.9 million people were found to be infertile. As per the World Health Organization, one in every six couple suffers from infertility related issues.
• Infertility is caused by different reasons including physiological dysfunction, STD (sexually transmitted diseases), anatomical or genetic disorder, endocrinological and immunological problems. Malaria, chlamydia (STI) gonorrhea, and other existing diseases
• Physiological reasons that could cause infertility are a congenital malformation, tubal blockage, abnormal ovulation, low quality and quantity of sperm, and ejaculatory dysfunctions. Additionally, infection, pollution, higher age, and other environmental hazards may lead to infertility. The fertility rate has been decreasing for the last few years with an increasing rate of infertility throughout the world.
• The required treatment procedures are still out of reach for people due to the higher costs involved and country-wise regulatory issues, which are major factors restraining the infertility testing and treatment market. The higher cost of IVF procedures is a prominent restraining factor, and the treatment is still beyond the reach of numerous infertile couples. The cost depends on the type of treatment and the age of the woman seeking the treatment. The amount to be paid by a 35 year old or younger woman would be less, and the investment increases as the age of the woman increases.

North America to Capture Major Share of Global Infertility Testing and Treatment Market

Based on region, the global infertility testing and treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America held a prominent share owing to high incidence of infertility, rising awareness about Infertility testing among women, the rising age of first-time pregnancies in women, and the easy availability of ovulation and fertility monitors through e-commerce websites.

Expansion of the Asia Pacific market is majorly due to a rise in the number of women suffering from the lifestyle disorders, raising funding/investments toward the development of fertility and ovulation monitors, and surge in focus of both international and domestic players on the infertility test market in Asia Pacific.

Key Players Operating in Global Infertility Testing and Treatment Market

The global infertility testing and treatment market is highly fragmented, with the presence of various key players. Major Players operating in the global infertility testing and treatment market are:

• Illumina, Inc.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• Delta Diagnostics
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific, Inc.
• Vitrolife
• FUJIFILM Irvine Scientific, Inc.
• Merck & Co., Inc.
• Genea Limited
• Ferring B.V.
• Swiss Precision Diagnostics
• Church & Dwight
• Prestige Brands Holdings
• bioZhena
• Fairhaven Health
• Geratherm Medical
• Hilin Life Products
• AdvaCare Pharma (US),

Global Infertility Testing and Treatment Market: Research Scope

Global Infertility Testing and Treatment Market, by Gender

• Male infertility
  • Testing
    • Oxidative Stress Analysis
    • Computer-Assisted Semen Analysis (CASA)
    • Microscopic Examination
    • DNA Fragmentation
    • Sperm Penetration Assay
    • Sperm Agglutination
    • Others
  • Treatment
    • Sperm Retrieval Treatment
    • Testicular Sperm Extraction (TESE)
    • Assisted Reproductive Techniques (ART)
    • In Vitro Fertilization (IVF)
    • Vasectomy Reversal
    • Microsurgical Sperm Aspiration
    • Varicocele Repairs
    • Intrauterine Insemination (IUI)
    • Intracytoplasmic Sperm Injection (ICSI)
• Female infertility
  • Testing
    • Ovulation Testing
    • Laparoscopy
    • Ovarian Reserve Testing
    • Hysterosalpingography
    • Transvaginal Ultrasound
    • Hormonal Level Testing
    • Others (Genetic Testing)
  • Treatment
    • In Vitro Fertilization (IVF)
    • Intrauterine Insemination (IUI)
    • Drug & Hormone Therapies

Global Infertility Testing and Treatment Market, by End-user

• Hospitals
• Fertility & Surgical Centers
• Diagnostic Centers
• Others

Global Infertility Testing and Treatment Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa